Loading data for NEUP — first visit, this takes a few seconds.
Neuphoria Therapeutics In... (NEUP)
NasdaqGM: NEUP
· Real-Time Price · USD
3.99
+0.00 (0.00%)
At close: Aug 19, 2026, 12:59 PM
Neuphoria Therapeutics Inc. (NEUP) Stock Price, Analysis & Data
0.00% (1D)
| Bid | n/a |
| Market Cap | 21.56M |
| Revenue (ttm) | -13.27K |
| Net Income (ttm) | -17.43M |
| Beta | n/a |
| EPS (ttm) | -7.9 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.64 |
| P/B (ttm) | 0.73 |
| P/S (ttm) | -1625.36 |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 16,377 |
| Avg. Volume (20D) | 200,520 |
| Open | 4.03 |
| Previous Close | 3.99 |
| Day's Range | 3.93 - 4.03 |
| 52-Week Range | 3.19 - 21.40 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NEUP
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2021
Employees 7
Stock Exchange NasdaqGM
Ticker Symbol NEUP
Website https://www.neuphoriatx.com
Financial Performance
In 2024, Neuphoria Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -15.49M, a decrease of -27.54%.
Financial StatementsEarnings Surprise
Neuphoria Therapeutics has released their quarterly earnings on May 15, 2026:
Page 1 of 2